Research Use Only. This comparison describes molecular identity, receptor-pathway context and analytical questions for laboratory research. It does not provide advice on human use, administration, exposure, dosing, treatment or performance outcomes.
The central distinction is not a contest between two interchangeable materials. The Core Research CJC-1295 No DAC + Ipamorelin 10mg listing is a two-component research blend, whereas Tesamorelin 10mg is presented as a single named peptide entity. A comparison therefore begins with identity and documentation: a blend has two analytes to distinguish, while a single-entity material has one declared active moiety whose exact salt or counter-ion still requires product-specific verification.
Comparison matrix
| Comparison field | CJC-1295 No DAC + Ipamorelin research blend | Tesamorelin research material |
|---|---|---|
| Commercial owner | CJC-1295 No DAC + Ipamorelin 10mg | Tesamorelin 10mg |
| Entity class | Two-component peptide blend. The CJC-labelled and ipamorelin-labelled constituents should be treated as separately identifiable analytes. | Single named peptide entity. Its exact supplied form must be taken from the product documentation, not inferred from a medicinal-product label. |
| Primary pathway question | GHRH-pathway context for the CJC-labelled constituent and ghrelin/GHSR-pathway context for ipamorelin are distinct research questions. A blend does not collapse them into one mechanism. | Tesamorelin is a growth-hormone-releasing-factor analogue in the scientific and regulatory literature. That literature should not be treated as an exposure recommendation for an RUO material. |
| Identity and mass | Do not assign a single molecular mass to the combined material. Sequence, modification, counter-ion and mass contribution of each constituent require the batch-specific product record. | Use a form-specific molecular mass only when the supplied form is documented. Active-moiety and salt/form claims are not interchangeable. |
| Analytical verification question | Assess whether the supplied documentation distinguishes both expected peptide signals and their individual identities. A single aggregate purity statement cannot establish the composition of each constituent. | Assess whether batch documentation links the named entity to the expected analytical identity. HPLC can describe separation behaviour; MS contributes mass/identity evidence but neither method alone establishes every material attribute. |
| Evidence layer | Mechanistic and pharmacology literature for the named constituents spans biochemical, animal and human-study contexts. Evidence should be labelled by layer rather than transferred from one constituent to the blend. | Tesamorelin has human pharmacology and regulatory literature. Those sources describe a regulated medicine context and do not establish equivalence to a separate RUO product. |
| Experimental-question fit | Useful where a study needs to distinguish GHRH-related and ghrelin-receptor signalling contexts within a deliberately multi-entity material. | Useful where a study is framed around the documented identity of a single GHRF analogue rather than a two-component blend. |
| Key limitation | “No DAC” is not a universal structural specification. Confirm what the supplier’s declared name means for that particular batch before importing a sequence, kinetic or mass claim from another CJC-labelled material. | Medicinal-product information for tesamorelin acetate must remain separate from the form and documentation of the Core Research research product. |
What the pathways do — and do not — establish
CJC-1295 literature is commonly discussed in relation to GHRH-receptor signalling; ipamorelin is described in primary pharmacology literature as a selective growth-hormone-secretagogue/ghrelin-receptor agonist.[1] These labels identify different pathway contexts. They do not establish that a combined commercial blend has a single fixed kinetic profile, a shared analytical signature, or a preferred outcome in a human setting.
Tesamorelin is described in FDA prescribing information for EGRIFTA SV as a growth-hormone-releasing-factor analogue and as tesamorelin acetate in that licensed presentation.[2] That regulatory record is relevant for identity disambiguation only. It does not convert an RUO catalogue product into the licensed medicine, confirm the same salt/form, or supply a laboratory protocol.
How to select the correct research material for an experimental design
Start with the experimental question rather than a claimed physiological outcome. A design examining whether a preparation contains separately documentable GHRH-related and GHSR-related constituents needs a blend-aware analytical plan. A design requiring a single named GHRF analogue instead needs a product record that identifies the supplied form unambiguously. In both cases, record the product owner, batch identifier, declared format and the methods shown on the available analytical documentation.
For the narrower structural issue of CJC-1295 with and without DAC, use the dedicated CJC-1295 DAC versus No-DAC comparison. It owns that pairwise sub-intent; this page deliberately remains a category-level blend-versus-single-entity matrix.
Documentation and analytical context
The relevant pre-experimental record is the product-specific documentation, not a generic percentage claim. The Certificate of Analysis portal and supplier-verification page explain the available documentation routes. When a document does not identify the exact form, modification or counter-ion, record that uncertainty rather than completing the field from a database entry for a similarly named material.
What this comparison does not establish
This matrix does not rank materials as stronger, safer, more effective or appropriate for any human outcome. It does not supply a preparation method, exposure regimen, dosing instruction or administration route. It also does not establish batch quality: that conclusion requires the documentation associated with the specific material under study.
Related research resources
- Growth Peptides Research Catalogue
- CJC-1295 No DAC + Ipamorelin 10mg
- Tesamorelin 10mg
- CJC-1295 DAC versus No-DAC structural comparison
- Batch Certificate of Analysis Verification
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PubMed 9849822.
- US Food and Drug Administration. EGRIFTA SV (tesamorelin) prescribing information. FDA label.
- Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of growth hormone-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683. This source is used for general CJC-1295 literature context, not to assign a form to the Core Research No-DAC blend.